FMC-220

FMC-220 is a covalent small molecule from Frontier Medicines. A covalent activator of the p53 Y220C mutant protein, designed to restore p53 tumour-suppressor function selectively. The company does not state its stage; it is aimed at tumours with the TP53 Y220C mutation. No clinical trial naming it is registered on ClinicalTrials.gov. No registered trial on ClinicalTrials.gov; the page gives no stage. It has not been shown to work in people.